

## Grifols completes development of very high sensitivity molecular test to detect SARS-CoV-2 virus

- *The company has developed the test in record time in a global coordinated effort of its facilities in San Diego, Barcelona and Bilbao, and has recently received the authorization of the Spanish Medicines and Medical Devices Agency (AEMPS) for its use in blood, plasma and respiratory samples.*
- *Grifols has a productive capacity of one million tests weekly in its plant in San Diego, U.S.*
- *The test technology, proprietary to Grifols, has a high sensitivity and specificity and uses the company's own Procleix® platform, through the Panther® analyzer, a completely automated system with a high throughput capacity per day.*

**Barcelona, May 5, 2020** - Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), has announced today it has completed the development of a specific TMA (Transcription-Mediated Amplification) molecular test that permits the detection of the SARS-CoV-2 virus in plasma, blood and respiratory samples, with a sensitivity equal or even superior to that of other molecular tests currently available, such as those based on PCR.

Thanks to this high sensitivity, the molecular test will also permit testing of pools of samples (pool strategy), multiplying the capacity of testing the population.

The TMA test is a complete and automated testing solution that includes all the reagents, from the preparation of the sample to getting a result. It is processed on Procleix® Panther® systems, each unit with an analysis capacity of more than 1,000 samples daily.

"Having sufficient molecular test capacity is critical to helping control this pandemic, and having a high-sensitivity test to handle a possible 'pooling' strategy is, without a doubt, a differentiating factor, which could make it feasible," said Victor Grifols Deu, Grifols co-CEO.

***The collective effort of teams in San Diego, Bilbao and Barcelona has enabled the accelerated test development and production in less than three months***

Grifols began developing its test to detect SARS-CoV-2 the first week of February, thanks to the combined efforts of its teams in San Diego (U.S.), Bilbao and Barcelona (Spain).

The design and manufacturing of the test took place in its San Diego facilities, where Grifols has its worldwide production of this type of test based on Transcription-Mediated Amplification technology, proprietary to Grifols.

Subsequently, the tests were validated in respiratory samples in the Grifols-Progenika laboratories in Bilbao, which have extensive experience in the development and validation of molecular diagnostic tools in any type of clinical sample.

“All of Grifols’ talent gave their complete dedication to develop, produce and validate this test in record time, an exceptional example of teamwork. We are very proud of the effort and commitment of our collaborators during these unprecedented times of crisis,” said Raimon Grifols Roura, Grifols co-CEO.

Grifols, with more than 100 years of history, is a global leader in diagnostic solutions and a standard in blood and plasma donation safety in countries such as the U.S. and Japan.

## Media contacts:

<b>Spain</b> Raquel Lumbreras <a href="mailto:Raquel.lumbreras@duomocomunicacion.com">Raquel.lumbreras@duomocomunicacion.com</a> Borja Gómez <a href="mailto:Borja.gomez@duomocomunicacion.com">Borja.gomez@duomocomunicacion.com</a> Duomo Comunicación – <b>Grifols press office</b> Tel. <b>+34 659 57 21 85 / +34 650 40 22 25</b>	<b>International</b> Brad Pick <b>Grifols Corporate Communications</b> <a href="mailto:Brad.pick@grifols.com">Brad.pick@grifols.com</a> Tel. <b>+34 93 571 00 02</b>
--	--

---

## About Procleix® Panther®

The Procleix® Panther® system is an automated molecular biology analyzer for high performance clinical diagnostics capable of processing more than 1,000 samples daily per unit.

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols’ economic impact in its core countries of operation was 8.5 billion euros. The company also generated 148,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.